IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants: https://lnkd.in/g95cKRSf
IDEAYA Biosciences’ Post
More Relevant Posts
-
And here's even more current analysis from Timothy Seymour on the #cannabis sector; part of the updates he provides on a weekly basis. $CNBS Listen here 👉 https://hubs.li/Q02FW5zh0 #investing #thematics #etfs #commentary
Amplify ETFS | Subscribe to CNBS Cannabis Weekly Recap
blog.amplifyetfs.com
To view or add a comment, sign in
-
Buy & Sell Signals How the price action of Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock ($FBIOP) is used to our Advantage: Stock Traders Daily has produced this trading report using a proprietary method. This methodology [...] Look at the Charts
How the price action of Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock ($FBIOP) is used to our Advantage
news.stocktradersdaily.com
To view or add a comment, sign in
-
And here's even more current analysis from Timothy Seymour on the #cannabis sector; part of the updates he provides on a weekly basis. $CNBS Listen now: https://hubs.li/Q02BzM7s0 #thematics #etfs
The Cannabis Recap - June 11, 2024
blog.amplifyetfs.com
To view or add a comment, sign in
-
IPO grants Daiichi patent for Edoxaban orally disintegrating composition. Inventive step & S.3(e) traversed. IN201917022577, family to EP3549585
To view or add a comment, sign in
-
The latest $CNBS #Cannabis Recap from Timothy Seymour is now available. Tim provides his insights on the current environment (market & legislative). Listen now: https://bit.ly/4aMFRpc #etfs #thematics #investing #markets
The Cannabis Recap - April 22, 2024
blog.amplifyetfs.com
To view or add a comment, sign in
-
📊 Dive into the latest insights! Discover how Takeda Pharmaceutical Co. ⚕ surged as the most crowded security (99) in the APAC large-cap category, with Aeon Corp 🏬 taking the lead in institutional supply utilization (21.22%). Uncover more findings and trends in our comprehensive report. Read the full report: https://lnkd.in/e66vJWaR
Hazeltree Monthly Shortside Report - Hazeltree
https://hazeltree.com
To view or add a comment, sign in
-
Cannabis capital markets continue to take investors on a rollercoaster ride. Capital raises and M&A fell in 2023; but with cannabis stocks rallying, new states legalizing, and the potential of rescheduling on the horizon, 2024 is shaping up to be an exciting year for the industry. Join MGO and Viridian Capital Advisors for the free live webinar “What’s in Store for Cannabis Capital Markets?” on Tuesday, February 20 at 1:30 p.m. PST (4:30 p.m. EST) to discuss data from the year in review and what the outlook is for 2024. We will also discuss how proposed rescheduling — and the elimination of 280E — could impact capital and M&A activity moving forward. Register now: https://hubs.la/Q02j_pK-0 #mgo #viridian #cannabis #cannabisindustry #capitalmarkets #investing #MandA #rescheduling #280E
To view or add a comment, sign in
-
-
Another View of Valuation vs. Leverage from the Viridian Deal Tracker. We update a second view of the valuation vs. leverage chart every week in the deal tracker. This chart shows leverage as measured by total liabilities to market cap. This measure has been shown every week for the last three years in our Viridian Credit Tracker credit scoring model and is the highest weighted leverage indicator out of the four we utilize. Moreover, the ratio has a rich history in bankruptcy prediction modeling, going back to early work by Beaver at Stanford and Altman at NYU. A version became the famous MAD ratio utilized by Drexel Burnham in the early days of junk bonds. The ratio is important because it incorporates the information present in equity prices and includes all liabilities, including payables and tax accruals, as well as debt and leases. It is an excellent credit screening tool because it reacts more quickly than purely financially driven measures like Debt/EBITDA. #cannabis #cannabisdebt #creditmodel
Welcome
https://dealtracker.viridianca.com
To view or add a comment, sign in
-
A late trading day bullish note from Jefferies on biotech name Ardelyx Inc. ($ARDX) results in Ardelyx shares gaining as much as +7%. The Hammerstone Scrolling News Feed: 02:30:27 pm $ARDX Ardelyx shares have 10%-15% upside on HR-5074 bill passage: Jefferies says in late day note. 02:45:54 pm $ARDX extending gains after JEFF comments, up 3.6% on the day. 03:00:39 pm $ARDX +7% - trading at 7-year highs - more - JEFF reit'd their Buy rating and $11 PT earlier - says that Congress has moved HR-5074 into the "markup phase," meaning the bill has increased odds of passing. If HR-5074 passes, a short-term overhang on Ardelyx's Xphozah will be removed, assuring Xphozah's rev growth into 2029 vs. 2027 @ JEFF
To view or add a comment, sign in
-
-
Investor with 19 Years' Experience | Join Like-Minded Subscribers for Market Insights & Investing Tips via My Newsletters
Music to an investor’s ears! 🎻 🎶 Biotech company Illumina (ILMN) is being forced to divest from its cancer-testing subsidiary, Grail. ILMN is part of the S&P 500 index. Grail will be too small for the index when it spins off, and all index-tracking funds will be forced to sell the stock! This forced sale has NOTHING to do with the fundamentals of Grail and everything to do with the restrictive mandates of institutional funds. This could present a fantastic opportunity for individual investors and highlights one of the HUGE advantages we have over institutions. I’ll certainly do more research into this! Any of you interested in buying Grail shares? Quote below is from FT article: https://lnkd.in/dZYd3kza #InvestmentOpportunities #IndividualInvestors #GrailSpinoff
To view or add a comment, sign in
-